Evaluation of Pain and Inflammation After Injection of Lucentis vs Eylea for Treatment of Wet Macular Degeneration

• Status: Completed
• Trial end date: 2014-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to compare the post injection inflammation and pain seen after intravitreal injections of Ranibizumab vs Aflibercept.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Arshad Khanani
• Collaborator: Genentech, Inc.
• Treatments: Aflibercept; Ranibizumab

Criteria

Inclusion Criteria:

1. Able to provide informed consent and comply with study assessments for the full duration of the study

2. Age >/= 65 years

3. New onset Neovascular Age-Related Macular Degeneration or (See No.4)

4. Previously treated Neovascular Age-Related Macular Degeneration with Lucentis or Eylea intravitreal injections

5. Visual Acuity of 20/400 or better

6. No history of Post injection pain or inflammation with prior treatments -

Exclusion Criteria:

1. History of Endophthalmitis in either eye

2. Uncontrolled or symptomatic Dry Eye Syndrome

3. History of Anterior or Posterior Uveitis

4. History of Post injection pain or inflammation with prior treatments

5. Recent thromboembolic event(<3 months)

6. Pregnancy(positive pregnancy test) or Lactation/Premenopausal women not using adequate contraception -